1

2
Hindley Richard Mark Beecham P: Substituted thiazolidinedione derivatives.. Beecham Group, March 8, 1989: EP0306228-A1 (97 worldwide citation)

Compounds of formula (I): or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A represents a substituted or unsubstituted aromatic heterocyclyl group; R represents a hydrogen atom, an alkyl group, an acyl group, an a ...


3
Stokbroekx Raymond Antoine, Grauwels Gilbert Arthur Jules, Willems Marc: Antirhinoviral piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers.. Janssen Pharmaceutica, November 22, 1990: EP0398425-A1 (91 worldwide citation)

Piperidinyl, pyrrolidinyl and piperazinyl alkylphenol ethers of formula X is N or CH; Alk is C1-4alkanediyl; R and R are hydrogen, C1-4alkyl or halo; R is hydrogen, halo, cyano, C1-4alkyloxy, aryl or -COOR, with R being hydrogen, C1-4alkyl, arylC1-4alkyl, C3-6cycloalkylC1-4alkyl, C3-5alkenyl, C3-5al ...


4
Ainsworth Anthony Trevor, Smith David Glynn Beecham Phar: Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them.. Beecham Group, September 16, 1987: EP0236624-A2 (70 worldwide citation)

A compound of the general formula (I): or a pharmaceutically acceptable ester thereof; or a pharmaceutically acceptable salt thereof, wherein, R represents a substituted or unsubstituted aryl group or a substituted or unsubstituted benzofuranyl group, X represents a bond or -O-CH2- , R represents a ...


5
Chen Beining: Thiazole and oxazole derivatives for use in the treatment of prion diseases, cancer and conditions of the central nervous system as well as in the regulation of stem cells. The University Of Sheffield, Chen Beining, Harrison Goddard Foote, July 31, 2008: WO/2008/090382 (60 worldwide citation)

Compounds of the formula (I) are provided: Fomula (I) wherein X, Y, R1, R2 and R3 are as defined in the specification. The compounds may be useful in the treatment of various diseases and conditions, in particular prion diseases.


6

7
Li Song, Zhou Xinming, Zhong Wu, Zheng Zhibing, Xiao Junhai, Wang Lili, Liu Hongying, Xie Yunde: Urea compounds, preparation methods and pharmaceutical uses thereof. Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences Pla, Li Song, Zhou Xinming, Zhong Wu, Zheng Zhibing, Xiao Junhai, Wang Lili, Liu Hongying, Xie Yunde, CCPIT PATENT AND TRADEMARK LAW OFFICE, October 23, 2008: WO/2008/125014 (49 worldwide citation)

The urea compounds of formula I, pharmaceutically acceptable salts and solvates, their preparation methods, the pharmaceutical compositions comprising the said compounds and the uses as p38 kinase inhibitors thereof. The substituents are defined as the description.


8
Riedl Bernd Dr, Haebich Dieter Dr, Stolle Andreas Dr, Wild Hanno Dr, Endermann Rainer Dr, Bremm Klaus Dieter Dr, Kroll Hein Peter Dr, Labischinski Harald Prof Dr, Schaller Klaus Dr, Werling Hans Otto Dr: Oxazolidinones substituted by 5-membered heteroaryl group as antibacterial medicine. Bayer, January 24, 1996: EP0693491-A1 (40 worldwide citation)

3-Heteroaryl-2-oxazolidinone derivs. of formula (I) and their salts and S-oxides are new: R1 = azido, OH, OR2, OSO2R3 or NR4R5; R2 = 1-8C acyl or a protecting gp.; R3 = 1-4C alkyl, phenyl or (1-4C alkyl)phenyl; R4, R5 = H, 1-8C alkyl, 3-6C cycloalkyl, phenyl or amino protecting gp., or one of R4, R5 ...


9
Serrano Wu Michael H, Kwak Young Shin, Liu Wenming: New compounds. Novartis, Novartis, Pharma, Serrano Wu Michael H, Kwak Young Shin, Liu Wenming, MILSTEAD Mark W, November 8, 2007: WO/2007/126957 (36 worldwide citation)

The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.


10
Johnstone Craig, Mckerrecher Darren, Pike Kurt Gordon: Compounds. Astrazeneca, Astrazeneca, Johnstone Craig, Mckerrecher Darren, Pike Kurt Gordon, ASTRAZENECA, September 1, 2005: WO/2005/080360 (33 worldwide citation)

Compounds of Formula (I) wherein: R1 is methyl; R2 is selected from -C (O) NR4R5, SO2NR4R5, S (O) pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from ...